Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent

Anti-Cancer Drug Design

Volumn 15, Issue 1, 2000, Pages 29-41

  Mendel, Dirk B ^a   Laird, A Douglas ^a   Smolich, Beverly D ^a   Blake, Robert A ^a   Liang, Congxin ^a   Hannah, Alison L ^a   Shaheen, Raymond M ^b   Ellis, Lee M ^b   Weitman, Steve ^c   Shawver, Laura K ^a   Cherrington, Julie M ^a  

^a SUGEN INC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CTRC Institute for Drug Development   (United States)

Author keywords

Angiogenesis; Cancer; Indolinones; SU5416

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; INDOLES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 12244277954     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Adnane J., Gaudray P., Dionne C.A., Crumley G., Jaye M., Schlessinger J., Jeanteur P., Birnbaum D., Theillet C. (1991) BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancer. Oncogens, 6, 659.
2. Albini A., Soldi R., Giunciuglio D., Giraudo E., Benelli R., Primo L., Noonan D., Salio M., Camussi G., Rockl W., Bussolino F. (1996) The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nature Medicine, 2, 1371.
3. Angelov L., Salhia B., Roncari L., McMahon G., Guha A. (1999) Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Research, 59, 5536.
4. Antonian L., Yang C., Sukebuntherng J., Fong T.A.T., Shenoy N., Schreck R., Wagner G., Shawver L. (1999) The pharmacokinetic and pharmacodynamic properties of SU5416, a novel VEGF receptor inhibitor. In: Proceedings of the 90th Annual Meeting, American Association for Cancer Research, April 10-14, Philadelphia, PA. Abstract no. 2568.
5. Armesilla A.L., Lorenzo E., Gomez del Arco P., Martinez-Martinez S., Alfranca A., Redondo J.M. (1999) Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Molecular and Cellular Biology, 19, 2032.
6. Bergers G., Javaherian K., Lo K.-M., Folkman J., Hanahan D. (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808.
7. Bais C., Sanomasso B., Coso O., Arvanitakis L., Raaka E.G., Gutkind J.S., Asch A.S., Cesarman E., Gerhengorn M.C., Mesri E.A. (1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature, 391, 86.
8. Brogi E., Wu T., Namiki A., Isner J.M. (1994) Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation, 90, 649.
9. Cherrington J.M., Laird A.D., Strawn L., Shenoy N., Tang F., Blake R., Yamada Y., Yonekura K., McMahon G., Shawver L., (1999) Activity profile of SU5416, a small molecule Flk-1/KDR inhibitor, in tumor xenograft models. Clinical Cancer Research, Supplement, Abstract no. 410.
10. Cherrington J.M., Strawn L.M., Shawver L.K. (2000) New paradigms for the treatment of cancer; the role of anti-angiogenesis agents. Advances in Cancer Research, 79, 1.
11. Clauss M., Weich H., Breier G., Knies U., Rockl W., Waltenberger J., Risau W. (1996) The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Journal of Biological Chemistry, 271, 17629.
12. de Jong J.S., van Diest P.J., van der Valk P., Baak J.P. (1998) Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. Journal of Pathology, 184, 53.
13. Decker H.J.H., Weidt E.J., Breiger J. (1997) The von Hipped Lindau tumor suppressor gene: a rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Cancer Genetics and Cytogenetics, 93, 74.
14. Derosane C.F., Hajitou A., Calberg-Bacq C.M., Nusgens B.V., Lapiere C.M. (1997) Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Research, 57, 5590.
15. Enholm B., Paavonen K., Ristimanki A., Kumar V., Gunji Y., Klefstrom J., Kininen L., Laiho M., Olofsson B., Joukov V., Eriksson U., Alitolo K. (1997) Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene, 14, 2475.
16. Ensoli B., Sirianni M.C. (1998) Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology. Critical Reviews in Oncogenes, 9, 107.
17. Eppenberger U., Kueng W., Schlaeppi J.M., Roesel J.L., Benz C., Mueller H., Matter A., Zuber M., Luescher K., Litschgi M., Schmitt M., Foekens J.A., Eppenberger-Castori S. (1998) Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. Journal of Clinical Oncology, 16, 3129.
18. Ferrara N. (1999) Molecular and biological properties of vascular endothelial growth factor. Journal of Molecular Medicine, 77, 527.
19. Finkenzeller G., Sparacio A., Technau A., Marme D., Seimeister G. (1997) SP1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene, 15, 669.
20. Folkman J. (1972) Anti-angiogenesis: new concept for theory of solid tumors. Annals of Surgery, 175, 409.
21. Folkman J. (1995) Angiogenesis in cancer, vascular, rhematoid and other disease. Nature Medicine, 1, 27.
22. Fong G.H., Zhang L., Bryce D.M., Peng J. (1999) Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development, 13, 3015.
23. Fong T.A.T., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K.P., McMahon G. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Research, 59, 99.
24. Fontanini G., Bigini D., Vignati S., Basolo F., Mussi A., Lucchi M., Chine S., Angeletti C.A., Harris A.L., Bevilacqua G. (1995) Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. Journal of Pathology, 177, 57.
25. Fontanini G., Lucchi M., Vignati S., Mussi A., Ciardiello F., De Laurentiis M., De Placido S., Basalo F., Angeletti C.A., Bevilacqua G. (1997) Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. Journal of the National Cancer Institute, 89, 881.
26. Fukumura D., Xavier R., Sugiura T., Chen Y, Park E.C., Lu N., Selig M., Nielsen G., Taksir T., Jain R.K., Seed B. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell, 94, 715.
27. Gale N.W., Yancopoulos G.D. (1999) Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Development, 13, 1055.
28. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., Ferrara N. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. Journal of Biological Chemistry, 273, 30336.
29. Gill P., Arastéh K., Jacobs M., Friedman-Kien A., Miles A., Gracey S., Hannah A., Langecker P. (1999) A multicenter dose escalating study of SU5416 in patients with cutaneous AIDS-related Kaposi's sarcoma. In Proceedings of the 39th ICAAC Conference, September 26-29, San Francisco, CA, Abstract 1160, p. 490.
30. Hanahan D., Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353.
31. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya, M. (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proceedings of the National Academy of Sciences, USA, 95, 9439.
32. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegland S.J. (1999) Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science, 284, 1994.
33. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science, 246, 1309.
34. Lida S., Katoh O., Tokunaga A. (1994) Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract. Biochemical Biophysical Research Communications, 199, 113.
35. McMahon G., Sun L., Liang C., Tang C. (1998) Protein kinase inhibitors: structural determinants for target specificity. Current Opinion in Drug Discovery and Developmnet, 1, 131.
36. Matsuyama K., Chiba Y., Sasaki M., Tanaka H., Muraoka R., Tanigawa N. (1998) Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Annals of Thoracic Surgery, 65, 1405.
37. Meyer M., Clauss M., Lepple-Wiemhues A., Waltenberger J., Augustin H.G., Ziche M., Lanz C., Buttner M., Rziha H.J., Dehio C. (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO Journal, 18, 363.
38. Millauer B., Plate K.H., Shawver L.K., Risau W., Ullrich A. (1994) Glioblastoma growth inhibited in vivo by dominant-negative Flk-1 mutant. Nature, 367, 576.
39. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., Schlessinger J. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955.
40. Nakamoto T., Chang C.S., Li A.K., Chodak G.W. (1992) Basic fibroblast growth factor in human prostate cancer cells. Cancer Research, 52, 571.
41. Nicosia R.F., Nicosia S.V., Smith M. (1994) Vascular endothelial growth factor, platlet-derived growth factor, and insulin-like growth factor-1 promote aortic angio-genesis in vitro. American Journal of Pathology, 145, 1023.
42. Park J.E., Chen H.H., Winer H., Houck K.A., Ferrara N. (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. Journal of Biological Chemistry, 269, 25646
43. Pedram A., Razandi M., Levin E.R. (1998) Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. Journal of Biological Chemistry, 273, 26722.
44. Plate K.H., Breier G., Weich H.A., Mennel H.D., Risau W. (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. International Journal of Cancer, 59, 520.
45. Rosen L., Mulay M., Mayers A., Kabbinavar F., Rosen P., Cropp G., Hannah A. (1999) Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. In Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology, May 15-18, Atlanta, GA, Abstract 618.
46. Sato N., Beitz J.G., Kato J., Yamamoto M., Clark J.W., Calabresi P., Frackelton A., Jr (1993) Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. American Journal of Pathology, 142, 1119-30.
47. Seghezzi G., Patel S., Ren C.J., Gualandris A., Pintucci G., Robbins E.S., Shapiro R.L., Galloway A.C., Rifkin D.B., Mignatti P. (1998) Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. Journal of Cell Biology, 141, 1659.
48. Shaheen R.M., Davis D.W., Liu W., Zebrowski B.K., Wilson M.R., Bucana C.D., McConkey D.J., McMahon G., Ellis L.M. (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor (VEGF) receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Research, 59, 5412.
49. Shawver L.K, Lipson K.E., Fong T.A.T., McMahon G., Plowman G.D., Strawn L.M. (1997) Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today, 2, 50.
50. Singh R.K., Llansa N., Bucana C.D., Sanchez R., Koura A., Fidler I.J. (1996) Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell Growth and Differentiation, 7, 397.
51. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. (1998) Neurophilin-1 is expressed by endothelail and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735.
52. Strawn L.M., Shawver L.K. (1998) Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opinion on Investigational Drugs, 7, 553.
53. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., Tang C. (1998) Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular RTKs. Journal of Medicinal Chemistry, 41, 2588.
54. Sundberg C., Lungstrom M., Lindmark G., Gerdin B., Rubin K. (1993) Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. American Journal of Pathology, 143, 1377.
55. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., Ellis L.M. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Research, 55, 3964.
56. Tsai J.-C., Goldman C.K., Gillespie G.Y. (1995) Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. Journal of Neurosurgery, 82, 864.
57. Vajkoczy P., Menger M.D., Vollmar B., Schilling L., Schmiedek P., Hirth K.P., Ullrich A., Fong T.A.T. (1999) Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia, 1, 31.
58. Wang D., Huang H.J., Kazlauskas A., Cavanee W.K. (1999) Induction of vascular endothelial growth factor expression by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Research, 59, 1464.
59. Yamaguchi F., Saya H., Bruner J.M., Morrison R.S. (1994) Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proceedings of the National Academy of Sciences, USA, 94, 484.
60. Zetter B.R. (1998) Angiogenesis and tumor metastasis Annual Review of Medicine, 49, 407.